Boasting a patent estate that the company's CEO said "covers everything that can be done" in antisense, Isis Pharmaceuticals Inc. entered a strategic alliance with Alnylam Pharmaceuticals Inc. that combines the pair's knowledge and expertise in the burgeoning field of RNAi. (BioWorld Today) Read More
